{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T14:54:45Z","timestamp":1771167285289,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T00:00:00Z","timestamp":1545782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41440-018-0187-1","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T09:26:43Z","timestamp":1545816403000},"page":"769-778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats"],"prefix":"10.1038","volume":"42","author":[{"given":"Lei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kobori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,26]]},"reference":[{"key":"187_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/hr.2016.137","volume":"40","author":"S Shibata","year":"2017","unstructured":"Shibata S, Ishizawa K, Uchida S. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. Hypertens Res. 2017;40:221\u20135.","journal-title":"Hypertens Res"},{"key":"187_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/hr.2015.19","volume":"38","author":"A Sato","year":"2015","unstructured":"Sato A. The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hypertens Res. 2015;38:367\u201374.","journal-title":"Hypertens Res"},{"key":"187_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10157-013-0827-3","volume":"18","author":"K Ueda","year":"2014","unstructured":"Ueda K, Nagase M. Mineralocorticoid receptor activation as an etiological factor in kidney diseases. Clin Exp Nephrol. 2014;18:16\u201323.","journal-title":"Clin Exp Nephrol"},{"key":"187_CR4","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1172\/JCI43124","volume":"121","author":"S Shibata","year":"2011","unstructured":"Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011;121:3233\u201343.","journal-title":"J Clin Invest"},{"key":"187_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/HJH.0b013e328325d861","volume":"27","author":"A Zhu","year":"2009","unstructured":"Zhu A, Yoneda T, Demura M, Karashima S, Usukura M, Yamagishi M, et al. Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats. J Hypertens. 2009;27:800\u20135.","journal-title":"J Hypertens"},{"key":"187_CR6","doi-asserted-by":"publisher","first-page":"e41896","DOI":"10.1371\/journal.pone.0041896","volume":"7","author":"K Kitada","year":"2012","unstructured":"Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, et al. Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats. PLoS ONE. 2012;7:e41896.","journal-title":"PLoS ONE"},{"key":"187_CR7","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1210\/en.2005-1167","volume":"147","author":"SJ Buss","year":"2006","unstructured":"Buss SJ, Backs J, Kreusser MM, Hardt SE, Maser-Gluth C, Katus HA, et al. Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. Endocrinology. 2006;147:2526\u201334.","journal-title":"Endocrinology"},{"key":"187_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","volume":"116","author":"SJ Hood","year":"2007","unstructured":"Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation. 2007;116:268\u201375.","journal-title":"Circulation"},{"key":"187_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/hr.2010.47","volume":"33","author":"G Kimura","year":"2010","unstructured":"Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertens Res. 2010;33:515\u201320.","journal-title":"Hypertens Res"},{"issue":"6","key":"187_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10157-018-1567-1","volume":"22","author":"Akira Nishiyama","year":"2018","unstructured":"Nishiyama A, Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. Clin Exp Nephrol. 2018;22:1231-9.","journal-title":"Clinical and Experimental Nephrology"},{"key":"187_CR11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/hr.2017.31","volume":"40","author":"H Takahashi","year":"2017","unstructured":"Takahashi H, Nakagawa S, Wu Y, Kawabata Y, Numabe A, Yanagi Y, et al. A high-salt diet enhances leukocyte adhesion in association with kidney injury in young dahl salt-sensitive rats. Hypertens Res. 2017;40:912\u201320.","journal-title":"Hypertens Res"},{"key":"187_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/01.hjh.0000226200.73065.5d","volume":"24","author":"P Guo","year":"2006","unstructured":"Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, et al. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens. 2006;24:1097\u2013104.","journal-title":"J Hypertens"},{"key":"187_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M. et al. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253\u2013390.","journal-title":"Hypertens Res"},{"key":"187_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"187_CR15","first-page":"241","volume":"18","author":"J Lindhorst","year":"2007","unstructured":"Lindhorst J, Alexander N, Blignaut J, Rayner B. Differences in hypertension between blacks and whites: an overview. Cardiovasc J Afr. 2007;18:241\u201347.","journal-title":"Cardiovasc J Afr"},{"key":"187_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/jim-2017-000445","volume":"65","author":"T Yoshimoto","year":"2017","unstructured":"Yoshimoto T, Furuki T, Kobori H, Miyakawa M, Imachi H, Murao K, et al. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med. 2017;65:1057\u201361.","journal-title":"J Investig Med"},{"key":"187_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jphs.2017.10.006","volume":"137","author":"L Li","year":"2018","unstructured":"Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, et al. Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats. J Pharmacol Sci. 2018;137:220\u20133.","journal-title":"J Pharmacol Sci"},{"key":"187_CR18","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","volume":"47","author":"M Yamada","year":"2017","unstructured":"Yamada M, Takei M, Suzuki E, Takakusa H, Kotsuma M, Washio T. et al. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2017;47:1090\u2013103.","journal-title":"Xenobiotica"},{"key":"187_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334.","journal-title":"Eur J Pharmacol"},{"key":"187_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373.","journal-title":"Eur J Pharmacol"},{"key":"187_CR21","doi-asserted-by":"publisher","first-page":"e0161706","DOI":"10.1371\/journal.pone.0161706","volume":"11","author":"D Karanovic","year":"2016","unstructured":"Karanovic D, Grujic-Milanovic J, Miloradovic Z, Ivanov M, Jovovic D, Vajic UJ, et al. Effects of single and combined Losartan and Tempol treatments on oxidative stress, kidney structure and function in spontaneously hypertensive rats with early course of proteinuric nephropathy. PLoS ONE. 2016;11:e0161706.","journal-title":"PLoS ONE"},{"key":"187_CR22","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1097\/01.ASN.0000026610.48842.CB","volume":"13","author":"A Nishiyama","year":"2002","unstructured":"Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition. J Am Soc Nephrol. 2002;13:2207\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"187_CR23","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370\u201376.","journal-title":"Nat Med"},{"key":"187_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","volume":"45","author":"A Nishiyama","year":"2005","unstructured":"Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005;45:710\u20136.","journal-title":"Hypertension"},{"key":"187_CR25","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1681\/ASN.2005020129","volume":"16","author":"Y Terada","year":"2005","unstructured":"Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1\/2, cyclin D1, and cyclin A. J Am Soc Nephrol. 2005;16:2296\u2013305.","journal-title":"J Am Soc Nephrol"},{"key":"187_CR26","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/ndt\/gfq197","volume":"25","author":"H Kawarazaki","year":"2010","unstructured":"Kawarazaki H, Ando K, Nagae A, Fujita M, Matsui H, Fujita T. Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. Nephrol Dial Transplant. 2010;25:2879\u201389.","journal-title":"Nephrol Dial Transplant"},{"key":"187_CR27","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","volume":"47","author":"M Nagase","year":"2006","unstructured":"Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084\u201393.","journal-title":"Hypertension"},{"key":"187_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/HCO.0b013e3281532b53","volume":"22","author":"H Hitomi","year":"2007","unstructured":"Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxidative stress. Curr Opin Cardiol. 2007;22:311\u20135.","journal-title":"Curr Opin Cardiol"},{"key":"187_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","volume":"43","author":"A Nishiyama","year":"2004","unstructured":"Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats. Hypertension. 2004;43:841\u20138.","journal-title":"Hypertension"},{"key":"187_CR30","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1681\/ASN.2005040390","volume":"16","author":"K Miyata","year":"2005","unstructured":"Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol. 2005;16:2906\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"187_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/01.ASN.0000108523.02100.E0","volume":"15","author":"A Nishiyama","year":"2004","unstructured":"Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, et al. The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol. 2004;15:306\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"187_CR32","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/ndt\/gfl780","volume":"22","author":"ML Onozato","year":"2007","unstructured":"Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant. 2007;22:1314\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"187_CR33","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension. 2017;69:870\u20138.","journal-title":"Hypertension"},{"key":"187_CR34","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/dom.13393","volume":"20","author":"M Lachaux","year":"2018","unstructured":"Lachaux M, Barrera-Chimal J, Nicol L, R\u00e9my-Jouet I, Renet S, Dumesnil A, et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes Metab. 2018;20:2399\u2013407.","journal-title":"Diabetes Obes Metab"},{"key":"187_CR35","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84:1821\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"187_CR36","doi-asserted-by":"publisher","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","volume":"97","author":"H Pei","year":"2018","unstructured":"Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e0254.","journal-title":"Medicine (Baltimore)"},{"key":"187_CR37","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453\u201363.","journal-title":"Eur Heart J"},{"key":"187_CR38","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1124\/jpet.109.158113","volume":"332","author":"A Nishiyama","year":"2010","unstructured":"Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther. 2010;332:1072\u201380.","journal-title":"J Pharmacol Exp Ther"},{"key":"187_CR39","doi-asserted-by":"crossref","unstructured":"Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2018 (in press).","DOI":"10.1038\/s41440-018-0158-6"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0187-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:20:10Z","timestamp":1684617610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-018-0187-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,26]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["187"],"URL":"https:\/\/doi.org\/10.1038\/s41440-018-0187-1","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,26]]},"assertion":[{"value":"7 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was in part a collaborative study with Daiichi-Sankyo Co., Ltd (to AN). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was also supported in part by the Salt Sciences Foundation (to AN).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}